19
Private & Confidential Private & Confidential Kevin Matthews - CEO Robin Cridland CFO and Company Secretary Revolymer October 2014

Revolymer - Itaconixitaconix.com/wp-content/uploads/revolymer-interim-results... · that include forward-looking terminology such as the words “targets ... (including in the merger

  • Upload
    vonhan

  • View
    218

  • Download
    4

Embed Size (px)

Citation preview

Private & Confidential

Private & Confidential

Kevin Matthews - CEO

Robin Cridland – CFO and Company Secretary

Revolymer

October 2014

Private & Confidential

Page 1

Disclaimer

These presentation materials (the "Presentation Materials") are being solely issued to and directed at persons who are qualified investors for the purposes of Section 86 of

the Financial Services and Markets Act 2000 ("FSMA") and have professional experience in matters relating to investments and who are investment professionals as

specified in article 19(5), or high net worth companies, etc. as specified in article 49 (2) (a) - (d), of the Financial Services and Markets Act 2000 (Financial Promotion) Order

2005 (the "Financial Promotion Order"). Accordingly, the Presentation Materials are exempt from the general restriction on the communication of invitations or inducements

to engage in investment activity and have therefore not been approved by an authorised person as would otherwise be required by section 21 of FSMA. Any investment to

which these Presentation Materials relate is available to (and any investment activity to which it relates will be engaged with) only those persons described in the above

paragraph. It is a condition of your reviewing these Presentation Materials that you fall within, and you warrant to Revolymer plc (the “Company”) that you fall within, the

category of persons described in Articles 19(5) or 49 of the Financial Promotion Order.

The Presentation Materials do not constitute or form any part of any offer or invitation to sell or issue or purchase or subscribe for any shares in the Company nor shall they

or any part of them, or the fact of their distribution, form the basis of, or be relied on in connection with, any contract with the Company relating to any securities. They are

being supplied to you solely for your information and may not be reproduced, forwarded to any other person or published, in whole or in part, for any other purpose. The

contents of these Presentation Materials have not been fully verified and no reliance may be placed for any purpose whatsoever on the information contained in these

Presentation Materials or on their completeness. Any reliance on this communication could potentially expose you to a significant risk of losing all of the property invested by

you or the incurring by you of additional liability. No representation or warranty, express or implied, is given by the Company, its directors or employees, or its professional

advisers as to the accuracy, fairness, sufficiency or completeness of the information, opinions or beliefs contained in these Presentation Materials. Save in the case of fraud,

no liability is accepted for any loss, cost or damage suffered or incurred as a result of the reliance on such information, opinions or beliefs.

Recipients of these Presentation Materials should conduct their own investigation, evaluation and analysis of the business, data and property described in this document.

Any person who is in any doubt about any investment to which these Presentation Materials relate should consult an authorised person specialising in advising on such

investments. Neither this document, nor any copy of it, may be taken or transmitted (including electronically) into the United States, Canada, Australia, Ireland, South Africa

or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws.

These Presentation Materials include “forward-looking statements” which include all statements other than statements of historical facts, including, without limitation, those

regarding the Company’s financial position, business strategy, plans and objectives of management for future operations and any statements preceded by, followed by or

that include forward-looking terminology such as the words “targets”, “believes”, “estimates”, “expects”, “aims”, “intends”, “can”, “may”, “anticipates”, “would”, “should”, “could”

or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the

Company’s control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or

achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s

present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of

these Presentational Materials.

The Company and its professional advisers expressly disclaim any obligation or undertaking to disseminate any updates or revisions in relation to any forward-looking

statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any

such statements are based, save as required by FSMA and/or the AIM Rules for Companies and AIM Rules for Nominated Advisers. As a result of these factors, the events

described in the forward-looking statements in these Presentation Materials may not occur. Your acceptance of the receipt of these Presentation Materials shall be deemed

to constitute your agreement to the above terms.

Private & Confidential

Page 2

Executive Management

Kevin Matthews - Chief Executive Officer

• Joined Revolymer Board as Chief Executive Officer on 29 September 2014

• Formerly at Isogenica Ltd, a business providing drug discovery services to the pharmaceutical

industry, where he served as CEO since 2009

• Kevin led the chemical technology company Oxonica as its CEO for 8 years, during which time he

completed its AIM listing in 2005 and secured numerous significant partnership deals and M&A

transactions

• He is currently serving as non-executive director of the FTSE 250 specialty chemicals company

Elementis plc

• Kevin has held senior roles at ICI, Albright & Wilson and Rhodia

• He is a graduate of the University of Oxford, where he was also awarded a DPhil in Organic

Chemistry

Robin Cridland - Chief Financial Officer & Company Secretary

• Rob has 25 years of pharma/tech business/corporate development and finance experience

• Rob joined Revolymer in September 2008 from Renovo Group plc, where he spent 7 years as

Executive Director of Finance and Business Development, floating the business on the Official List

in 2006 and signing a major licence with Shire in 2007

• He qualified as a chartered accountant at Coopers & Lybrand Deloitte, before moving on to senior

transactional roles at Enskilda Securities and senior finance and transactional roles at

GlaxoWellcome and GSK (including in the merger to form GSK, and integration projects)

• Rob has an MA from the University of Oxford and is a Fellow of the Institute of Chartered

Accountants in England and Wales

Private & Confidential

Page 3

Jack Keenan – Independent Non Executive Chairman

Formerly CEO & Chairman of Kraft International

CEO of Guinness, United Distillers & Vintners and an

executive director of Diageo

NEDs have included Body Shop, M&S, General Mills,

Tomkins; Senior Advisor to Oaktree Capital

Management

Kevin Matthews - CEO

20+ years senior management, BD and

corporate development experience

Formerly CEO of Isogenica and Oxonica

Serving NED of Elementis plc

Julian Heslop – Independent NED

Previously CFO of GlaxoSmithKline

Senior finance roles at ViiV Healthcare

(Chairman), Grand Metropolitan and Imperial

Brewing and Leisure

Mike Townend - NED

20+ years experience in equity capital

markets including Lehman Brothers

Representative of IP Group

Robert Frost - NED

20+ years private equity experience

including Allianz Capital

Representative of Naxos Capital Partners

Bryan Dobson – Independent NED

30+ years in chemicals industry including

ICI and Croda

Most recently President Global

Operations for Croda

Board of Directors

Robin Cridland - CFO & Company Secretary

25 years pharma/tech BD, corporate

development and finance experience:

GSK merger, Renovo IPO,

Shire licence/investment, Revolymer IPO

Private & Confidential

Private & Confidential

Page 4

Revolymer H1 2014 Business Highlights “Polymer technology company that designs, develops and formulates novel polymers to

improve the performance of existing consumer products within large FMCG markets”

Consumer Specialties

• Focus on executing commercial deals in the high value consumer specialties business area

(e.g. household products, personal care):

• Global licence agreed with Solvay for use of encapsulation polymer technology

• Progressing a portfolio of other product development programmes towards

commercial deals (“multiple shots on goal”)

Nicotine Chewing Gum

• Commercialisation through the white / private label channel:

• US supply and distribution agreement with PL Developments

• Continued progress made in the EU regulatory approval process

• Continuing sales of nicotine gum in Canada through a Canadian retailer

Funding

Cash and cash equivalents at 30 June 2014 of £15.2m (2013: £19.7m), providing future

runway to deliver key commercial projects

Private & Confidential

Private & Confidential

Page 5

Revolymer Technology Overview

Polymer technology

Skin e.g.

moisturiser

• Revolymer’s portfolio of development programmes is based on its patented polymer technology

• Revolymer is applying these technologies to develop novel polymers for use in the next generation

of polymer-enhanced consumer products across a range of FMCG markets

Personal Care Medicated Gum

Hair e.g.

Styler

Dental e.g.

whitener

Encapsulated Peroxides

e.g. PAP, SPC

Household Products

Other Encapsulated

Actives e.g. enzymes and catalysts

Other e.g.

sealants

Nicotine Gum

Skin e.g.

moisturiser

Hair e.g.

Styler

Dental e.g.

whitener

Encapsulated Peroxides

e.g. PAP, SPC

Other Encapsulated

Actives e.g. enzymes and catalysts

Skin e.g.

moisturiser

Hair e.g.

Styler

Dental e.g.

whitener

Private & Confidential

Private & Confidential

Page 6

Specialty Materials Market

Key Attributes

Small % of final product – generally modest volumes

Limited price sensitivity – good margin business

Low substitution rates = + and –

Qualification processes normally lengthy (but dependent on market)

Business built on

Quality Product (value add pricing)

Close technical relationships

Private & Confidential

Private & Confidential

Page 7

Commercialisation Models

A: Licensing:

Logical business model for highly consolidated, large volume, cost sensitive, controlled markets

Successful licences can generate substantive ROCE, but The more execution elements that get transferred to licensee the greater the risk

of delay and changes in licensee priority/strategy Potential to part-mitigate risk with multiple licensing partners (different

applications)

B: Development of product capability: Logical business model for fragmented, relatively small volume high value

markets Potential to identify some early “low hanging fruit” to drive revenue Build greater control of short to medium term business timeline Build business capability to define own future Growth of ROCE will be incremental in nature and depend on identifying multiple

product lines

Private & Confidential

Private & Confidential

Consumer Specialties: Solvay Licence

• First commercial deal delivered in household products segment - Global licence of encapsulation

technology to Solvay for use with the cleaning and disinfecting active 6-phthalimido-

peroxyhexanoic acid (“PAP”), currently commercialised as Eureco(TM)

• Improved stability of PAP formulations applying Revolymer’s encapsulation technology

• Expanding the market for PAP into a broad range of fields including cleaning, disinfection and

deodorisation in solid, gel and liquid formulations of detergents

• Industry segments targeted by Solvay include laundry detergents and additives and dish wash

agents in the consumer, domestic, industrial and institutional markets

• Royalty payments on net sales of products containing encapsulation technology

• Technology validation paving the way for further licences in the household products segment

Page 8

Revolymer Partner

Polymer formulation

development

Formulation performance

testing

Formulation safety testing

Product Concept

*including early customer testing

Key milestones: delivered and future

Polymer formulation

development

Internal Formulation performance

and safety testing

Customer Formulation/

Product performance

and safety testing

Production scale-up

COMMERCIAL LICENCE

Customer acceptance

testing

Sales & royalties to Revolymer

Private & Confidential

Private & Confidential

Page 9

Consumer Specialties: Solvay - Supply Chain Positioning

(Institutional Market)

Active Manufacturer e.g. Solvay, Kemira,

OCI, Evonik

Institution e.g. hospitals,

restaurants, hotels

I - 2 I - 1

Distributor / Formulator

Solvay

I

Private & Confidential

Private & Confidential

Page 10

Consumer Specialties: Solvay - Supply Chain Positioning

(Consumer Market)

Private Label Producer e.g. McBride

Brand Producer

e.g. RB, Unilever, PnG, Henkel

Active Manufacturer e.g. Solvay, Kemira,

OCI, Evonik

Retailer Consumer

C - 3 C C -1 C - 2

Solvay

Private & Confidential

Private & Confidential

Page 11

• Progressing a portfolio of other projects towards commercial deals – a number now at

an advanced stage

• Household Products: further deals for encapsulation technology applied to

stabilisation of laundry and non-laundry cleaning actives subject to on-going

discussions (e.g. SPC)

• Personal Care: new products being developed for global brand owners

• TSB grant funding to develop marine fouling control coatings – 2-year funded

collaborative research project with AkzoNobel’s International Paint Ltd, the University

of Liverpool and Newcastle University

Consumer Specialties: Other Progress

Private & Confidential

Private & Confidential

Building a nicotine gum franchise - Significant developments made in the commercialisation, through the

white/private label channel, of our proprietary nicotine gum products

US

• Supply and distribution agreement for the United States of America signed with PL Developments LLC

(“PLD”)

• Preparation of an application for marketing approval in the US

Europe

• Sep 2014: confirmation of compliance with the principles and guidelines of good manufacturing

practice (“GMP”) from the MHRA

• Nov 2013: Submitted regulatory filings for marketing approval of our nicotine gum in Europe

• Oct 2013: Distribution agreement signed for nicotine gum in Poland, Hungary, Czech & Slovak

Republics

• Progressing towards commercial deals in other key European markets

Canada

• Continued sales of Revolymer’s proprietary nicotine gum in Canada following award of a contract to

supply a leading Canadian pharmacy chain

• Patent infringement proceedings ongoing

Page 12

Nicotine Gum: Progress

Private & Confidential

Private & Confidential

Page 13

Nicotine Gum: PLD - US Supply Chain Positioning

Manufacturer Retailer

e.g. pharmacy chains & grocery multiples

Consumer

C - 3 C C - 2

Distributor

PLD

C - 1

Private & Confidential

Private & Confidential

Nicotine Gum: Product Commercialisation Key Milestones: delivered and future

US

Application to the FDA

Sale & distribution agreements

Sales & revenue

Product concept

Polymer formulation

development

Product development

Performance testing

Product development

Safety testing

Regulatory approval for

sale

Europe

Application for marketing authorisation

Sale & distribution agreements

Sales & revenue

Product concept

Polymer formulation

development

Product development

Performance testing

Product development

Safety testing

Regulatory approval for

sale

Page 14

Canada

Application for marketing authorisation

Regulatory approval for

sale

Sale & distribution agreements

Sales & revenue

Product concept

Polymer formulation

development

Product development

Performance testing

Product development

Safety testing

Private & Confidential

Private & Confidential

Financials: Group Income Statement

Page 15

Unaudited

6 Months to 30 June

2014

Unaudited

6 Months to 30 June

2013

Audited

Year to 31 December

2013 £000 £000 £000

Revenue 366 22 528

Cost of sales (227) (276) (871)

Gross (loss)/profit 139 (254) (343)

Other operating income 30 166 194

Administrative expenses (2,917) (2,871) (5,328)

Group operating loss (2,748) (2,959) (5,477)

Finance income 57 105 193

Loss for the year before tax (2,691) (2,854) (5,284)

Taxation expense - - -

Loss for the year (2,691) (2,854) (5,284)

Private & Confidential

Private & Confidential

Financials: Group Statement of Financial Position

Page 16

Unaudited

As at 30 June

2014

Unaudited

As at 30 June

2013

Audited

As at 31 December

2013 £000 £000 £000

Non-current assets

Property, plant and equipment 403 391 364

403 391 364

Current assets

Inventories 203 - 168

Trade and other receivables 340 328 534

Investments 13,000 17,000 15,500

Cash and cash equivalents 2,183 2,659 2,182

15,726 19,987 18,384

Total assets 16,129 20,378 18,748

Total Equity 13,750 18,349 16,084

Current liabilities

Trade and other payables 2,213 1,825 2,314

Non-current liabilities

Finance lease obligations and other payables 166 204 350

Total liabilities 2,379 2,029 2,664

Total Equity and liabilities 16,129 20,378 18,748

Private & Confidential

Private & Confidential

Financials: Group Statement of Cash Flows

Page 17

Unaudited

6 Months to 30 June 2014

Unaudited

6 Months to 30 June 2013

Audited

Year to 31 December 2013

£000 £000 £000

Net cash outflow from operating activities (2,550) (2,154) (4,311)

Cash flows from investing activities

Interest received 44 27 193 Purchase of property, plant and equipment (126) (129) (183) Funds withdrawn from term deposits 2,500 - 1,500 Net cash inflow/(outflow) from investing activities 2,418 (102) 1,510

Cash received from issue of shares 133 16 84 Net cash inflow from financing activities 133 16 84

Net inflow/(outflow) in cash and cash equivalents 1 (2,240) (2,717) Cash and cash equivalents at beginning of year 2,182 4,899 4,899 Cash and cash equivalents at end of year 2,183 2,659 2,182

Private & Confidential

Private & Confidential

• First commercial deal in consumer specialities – key milestone

delivered

• Focus on further commercial deals in Consumer Specialties

• Progress made in the commercialisation of proprietary nicotine gum

products

• Increasing commercial leadership

Page 18

Summary – Progress Across All Areas Of The Business